JUNS

Jupiter Neurosciences, Inc. (JUNS) - Form 8-K Summary

Business Context and Reporting Period

Date of Report: July 20, 2026
Company: Jupiter Neurosciences, Inc., a clinical-stage pharmaceutical company focused on therapies for neuroinflammation and CNS disorders.
Event: Entry into a definitive Strategic Asset License Agreement with PharmAla Biotech Holdings Inc. regarding the ALA-002 program (an MDXX-class psychedelic investigational compound).

Key Financial Metrics and Transaction Terms

This filing details a licensing transaction rather than standard operating financial results. Key financial terms include:

• Upfront Consideration: Total of $3,333,333.
  • $1,500,000 in cash (net of a $600,000 escrow deposit previously made).
  • $1,833,333 in Jupiter common stock (Equity Consideration), subject to a VWAP reset mechanic and a 120-day lock-up.
• Development Milestones: Up to $23,333,333.
  • $3,333,333 upon first dosing in a Phase 3 trial (50% cash, 50% cash or stock).
  • $20,000,000 upon first FDA NDA approval (cash).
• Commercialization Milestones: Up to $73,333,333 based on net sales thresholds of $333.3M, $1.0B, and $2.0B.
• Royalties: 3% of net sales in the Territory, commencing after the third commercialization milestone is achieved.

Material Changes and Strategic Impact

The definitive agreement supersedes a non-binding summary of terms filed on May 20, 2026. Jupiter has secured an exclusive, royalty-bearing, sublicensable license to develop, manufacture, and commercialize products incorporating ALA-002 solely in the United States. PharmAla retains rights outside the U.S. Jupiter assumes sole responsibility for development, regulatory filings, and manufacturing within the Territory.

Outlook, Risks, and Contingencies

• Equity Issuance: Shares will be issued within 30 days of the effective date based on a 20-day VWAP. A VWAP reset mechanic ensures PharmAla receives full value if the stock price drops; if the price falls below a specific floor, cash may be required instead of shares.
• Regulatory Cap: The equity issuance is subject to a Nasdaq 19.99% exchange cap unless stockholder approval is obtained.
• Termination Rights:
  • Either party may terminate for uncured material breach (90-day cure period, reduced to 5 days for critical payments).
  • PharmAla may terminate if Jupiter fails to meet development milestones.
  • Jupiter may terminate for convenience with 180 days' notice.
• Change of Control: Jupiter cannot consummate a change of control involving a competing business without PharmAla's consent.

Investor Verification Checklist

• Verify the exact number of shares to be issued once the 20-day VWAP is calculated and confirm if stockholder approval is required to exceed the 19.99% Nasdaq cap.
• Confirm the release of the $600,000 escrow deposit and the timing of the $1,500,000 initial cash payment.
• Review the full text of the Strategic Asset License Agreement (Exhibit 10.1) for specific definitions of "Net Sales" and the "Equity Floor Price."
• Assess the impact of the 120-day lock-up period on PharmAla's ability to trade the received shares.
• Monitor the timeline for the filing of the registration statement for the issued shares (required within 30 days of issuance).